Will FDA Advisory Committee Consider Acomplia, and When?
The U.S. Food and Drug Administration advisory committee that is expected to weigh in on the new anti-obesity drug Acomplia (rimonabent) prior to an FDA decision on approval apparently does not intend to take up the drug at its December meeting.
The FDA’s Endocrinologic and Metabolic Drugs [...]
Sanofi-Aventis Seeks to Shut Down News Coverage by the Acomplia Report
Sanofi-Aventis, developer of the much touted diet drug Acomplia (rimonabant) , has announced its intention to try and shut down the independent Acomplia Report, denying hundreds of thousands of obese and overweight individuals this unbiased source of news about the drug and efforts to bring it to [...]
Will We See FDA Movement on Acomplia in January?
In the absence of any real news on where the FDA decision process stands on the new anti-obesity drug Acomplia (rimonabant), speculation has begun to focus on whether a key agency rimonabant advisory committee will consider the merits of the drug at a January meeting.
[...]
Is No News Good News for Acomplia
In the past month, the new anti-obesity drug Acomplia (rimonabant) has virtually disappeared from the news, leading a number of the millions of overweight men Acomplia (rimonabant) and women who had been hoping it might be available before the end of the year to wonder what’s going on.
Well, [...]
Sanofi Says Everything Is “Going Exactly According to Schedule” for Acomplia
A top executive of Sanofi-Aventis Acomplia (rimonabant) , developer of the new anti-obesity drug Acomplia (rimonabant), said on November 8th that ” everything is going exactly according to schedule” for FDA approval in early 2006, even while conceding that no date has Acomplia (rimonabant) yet been set [...]
